The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy.

Eur Cytokine Netw. 1999 Jun;10(2):219-26. Unique Identifier : AIDSLINE MED/99328729
Zamauskaite A; Yaqoob MM; Madrigal JA; Cohen SB; The Anthony Nolan Bone Marrow Trust, The Royal Free Hospital,; Pond Street, Hampstead, London, NW3 2QG, United Kingdom.

Abstract: We have analysed the frequency of cytokine-producing T cells in different dialysis groups (haemodialysis; HD and peritoneal dialysis; PD) over time. Although we saw no difference in type 1 cytokine production (IL-2 and IFN-gamma) in either dialysis group, there was a clear increase in the percentage of T cells spontaneously producing the type 02 cytokines in the PD group (IL-4, r = 0.558, P < 0.05; IL-10, r = 0.527, p < 0.05). Our patient group was carefully selected to include patients with an ongoing autoimmune disease, insulin dependent diabetes mellitus (IDDM) (DN group) and chronic glomerulonephritis (GN), which are common reasons of end stage renal failure. As expected there was no increase in the spontaneous production of either IL-4 or IL-10 in either disease group with patients undergoing HD treatment. However, there was a clear correlation with the frequency of T cells producing IL-4 (r = 0.755, P < 0.05) and IL-10 (r = 0.725, P < 0.05) and time on dialysis in the PD patients with DN, but not those with GN. Much work has suggested that the pathogenesis of IDDM is associated with a Th1 dominated response. We show here that this response is skewed towards a Th2 response after long term treatment with PD. This work demonstrates that the immunological effects of different dialysis modalities on patients with different diseases vary. This may go some way to explain why certain patient groups have more complications with different dialysis modalities.

Keywords: JOURNAL ARTICLE Autoimmune Diseases/COMPLICATIONS/IMMUNOLOGY/THERAPY Comparative Study *CD4 Lymphocyte Count Diabetes Mellitus, Insulin-Dependent/COMPLICATIONS/IMMUNOLOGY/ THERAPY Diabetic Nephropathies/*IMMUNOLOGY/THERAPY Glomerulonephritis/COMPLICATIONS/IMMUNOLOGY/THERAPY Hemodialysis Human Interleukin-10/SECRETION Interleukin-4/SECRETION Kidney Failure, Chronic/ETIOLOGY/*IMMUNOLOGY/THERAPY *Peritoneal Dialysis Support, Non-U.S. Gov't *Th2 Cells/SECRETION Time Factors
991130
A99B1065

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .